Nasser Elhawary

Prof. Nasser Elhawary

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2022 in Human Genomics
Verified
Journal Article
Open access
PDF file
NENasser Elhawary
Nasser Elhawary
IAImad A. AlJahdali
Imad A. AlJahdali
IAIman S. Abumansour
Iman S. Abumansour
EEEzzeldin N. Elhawary
Ezzeldin N. Elhawary
NGNagwa Gaboon
Nagwa Gaboon
OKOsama A. Kensara
Osama A. Kensara
This review discusses the epidemiology, pathophysiology, genetic etiology, and management of phenylketonuria (PKU). PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene. The prevalence of PKU varies widely among ethnicities and geographic regions, affecting approximately 1 in 24,000 individuals worldwide. Deficiency in the PAH enzyme or, in rare cases, the cofactor tetrahydrobiopterin results in high blood Phe concentrations, causing brain dysfunction. Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes). Severe phenotypes are classic PKU, and less severe forms of PAH deficiency are moderate PKU, mild PKU, mild hyperphenylalaninaemia (HPA), or benign HPA. Early diagnosis and intervention must start shortly after birth to prevent major cognitive and neurological effects. Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120–360 μmol/L throughout the life span. Additional treatments include the casein glycomacropeptide (GMP), which contains very limited aromatic amino acids and may improve immunological function, and large neutral amino acid (LNAA) supplementation to prevent plasma Phe transport into the brain. The synthetic BH4 analog, sapropterin hydrochloride (i.e., Kuvan®, BioMarin), is another potential treatment that activates residual PAH, thus decreasing Phe concentrations in the blood of PKU patients. Moreover, daily subcutaneous injection of pegylated Phe ammonia-lyase (i.e., pegvaliase; PALYNZIQ®, BioMarin) has promised gene therapy in recent clinical trials, and mRNA approaches are also being studied.

1 October 2013 in Disease Markers
Verified
Journal Article
Open access
PDF file
NENasser Elhawary
Nasser Elhawary
DHDoaa Hewedi
Doaa Hewedi
AAArwa Arab
Arwa Arab
STSalwa Teama
Salwa Teama
HSHassan Shaibah
Hassan Shaibah
NBNeda Bogari
Neda Bogari
Objective. We evaluated whether the methylenetetrahydrofolate reductase (MTHFR) 677C>T marker influences the risk and severity of Alzheimer's disease (AD) and whether AD is associated with homocysteine, vitamin B12, and cholesterol levels in Egypt.Methods. Forty-three Alzheimer's cases and 32 non-AD controls were genotyped for the 677C>T polymorphism. Clinical characteristics and levels of homocysteine, vitamin B12, and cholesterol were assessed.Results. No significant differences in the frequencies of theMTHFRalleles or genotypes between AD cases and controls (P=0.14) were identified. The 677T mutant allele was significantly overrepresented in AD cases compared to controls (OR=2.22;P=0.03). The 677T/T frequency was three times higher in AD patients than in controls, which could increase plasma homocysteine levels. Severe cases of AD were the most frequent in patients with the T/T genotype (11.6%). The effect of theMTHFRpolymorphism on the risk of AD may be independent of homocysteine, vitamin B12, or even cholesterol levels.Conclusions. TheMTHFR677C>T polymorphism—especially the presence of one copy of the T allele—appears to confer a potential risk for the development of AD. The T/T genotype may contribute to hypercysteinemia as a sensitive marker.

15 November 2010 in Hemoglobin
Verified
Journal Article
Closed access
PDF file
EJEssam H. Jiffri
Essam H. Jiffri
NBNeda Bogari
Neda Bogari
KZKhaled H. Zidan
Khaled H. Zidan
STSalwa Teama
Salwa Teama
NENasser Elhawary
Nasser Elhawary
We have updated the dataset of the molecular spectrum of the β-thalassemia (β-thal) in Upper Egypt. Buccal swabs were analyzed from 94 unrelated patients with β-thal major (β-TM) using reverse dot-blot and multiplex amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). The most frequent mutation was IVS-I-110 (G>A) (57%). The IVS-I-110, IVS-I-6 (T>C) and IVS-I-1 (G>A) mutations accounted for 87% of the β-thal anomalies. The codon 39 (C>T) and frameshift codon (FSC) 6 (–A) (GAG>–GG) mutations were only detected in Al-Minya and Qina, respectively. We did not observe the IVS-II-745 (C>G) or –101 (C>T) mutations. Forty-three percent of Upper Egyptians were homozygotes. Our efforts were an important step to complete the mutation map of β-thal in Egypt restricted to Cairo and the Nile Delta regions. This study will help to develop preventative programs for Upper Egyptians. It addressed the genetic drift of the β-thal gene mutations in Africa, Asia, and Europe.

1 September 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
AAAbdullah R Alzahrani
Abdullah R Alzahrani
DMDoaa Mohamed
Doaa Mohamed
HNHebatallah H Abo Nahas
Hebatallah H Abo Nahas
DEDalia Alaa El-Din Aly El-Waseef
Dalia Alaa El-Din Aly El-Waseef
AAAbdulmalik Altamimi
Abdulmalik Altamimi
Essa M. SaiedEssa M. Saied
Essa M. Saied
Introduction: Pulmonary fibrosis (PF) and tissue remodeling can greatly impair pulmonary function and often lead to fatal outcomes. Methodology: In the present study, we explored a novel molecular interplay of long noncoding (Lnc) RNA CBR3-AS1/ miRNA-29/ FIZZ1 axis in moderating the inflammatory processes, immunological responses, and oxidative stress pathways in bleomycin (BLM)-induced lung fibrosis. Furthermore, we investigated the pharmacological potential of Trimetazidine (TMZ) in ameliorating lung fibrosis. Results: Our results revealed that the BLM-treated group exhibited a significant upregulation in the expression of epigenetic regulators, lncRNA CBR3-AS1 and FIZZ1, compared to the control group (P< 0.0001), along with the downregulation of miRNA-29 expression. Furthermore, Correlation analysis showed a significant positive association between lnc CBR3-AS1 and FIZZ1 (R=0.7723, p< 0.05) and a significant negative association between miRNA-29 and FIZZ1 (R=− 0.7535, p< 0.05), suggesting lnc CBR3-AS1 as an epigenetic regulator of FIZZ1 in lung fibrosis. BLM treatment significantly increased the expression of Notch, Jagged1, Smad3, TGFB1, and hydroxyproline. Interestingly, the administration of TMZ demonstrated the ability to attenuate the deterioration effects caused by BLM treatment, as indicated by biochemical and histological analyses. Our investigations revealed that the therapeutic potential of TMZ as an antifibrotic drug could be ascribed to its ability to directly target the epigenetic regulators lncRNA CBR3-AS1/ miRNA-29/ FIZZ1, which in turn resulted in the mitigation of lung fibrosis. Histological and immunohistochemical analyses further validated the potential antifibrotic effects of TMZ by mitigating the structural damage associated with fibrosis. Discussion: Taken together, our study showed for the first time the interplay between epigenetic lncRNAs CBR3-AS1 and miRNA-29 in lung fibrosis and demonstrated that FIZZ1 could be a downregulatory gene for lncRNA CBR3-AS1 and miRNA-29. Our key findings demonstrate that TMZ significantly reduces the expression of fibrotic, oxidative stress, immunomodulatory, and inflammatory markers, along with epigenetic regulators associated with lung fibrosis. This validates its potential as an effective antifibrotic agent by targeting the CBR3-AS1/miRNA-29/FIZZ1 axis.

16 April 2025 in International Journal of Environmental Health Research
Verified
Journal Article
Closed access
NENasser Elhawary
Nasser Elhawary
SESamar N. Ekram
Samar N. Ekram
HSHatem A. Sembawa
Hatem A. Sembawa
ETEmad Tashkandi
Emad Tashkandi
SBSahar Bannani
Sahar Bannani
AEAbdelrahman N. Elhawary
Abdelrahman N. Elhawary
This review provides descriptive evidence for the potential sociodemographic risk factors of race/ethnicity, younger age, and socioeconomic status, as well as evidence for the immigrant effect in women with breast cancer (BC) across world regions and countries. Using MEDLINE and the Web of Science on epidemiology, incidence/mortality rates, and social determinants, we searched a registry-based dataset and the reference lists of prior reviews of BC women (code C50) from the GLOBOCAN 2022 database and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program 2024. Globally, 1,959,256 new cases (26.7%) and 495,572 deaths (17.7%) were recorded in women aged <75 years in 2022. The age-standardized incidence rate (ASIR) of BC was the highest among countries with a very high Human Development Index (ASIR, 70.9), a high HDI (ASIR, 44.4), middle-low levels (ASIR, 33.6-32.5), driven by affluent lifestyles and a higher incidence of infectious diseases and infection-associated cancers. Besides, younger BC women are statistically more likely than older ones to have pathogenic germline variants in BC susceptibility genes (BRCA1/2, TP53, PALB2). The descriptive epidemiology presented in this review should be of global value to clinicians, researchers, and policymakers, considering the implementation and implications of population-based BC screening programs.

10 April 2018 in Human Genomics
Verified
Journal Article
Open access
PDF file
NENasser Elhawary
Nasser Elhawary
EJEssam H. Jiffri
Essam H. Jiffri
SJSamira Jambi
Samira Jambi
AMAhmad H. Mufti
Ahmad H. Mufti
ADAnas Dannoun
Anas Dannoun
MTMohammed T. Tayeb
Mohammed T. Tayeb
In individuals with Duchenne muscular dystrophy (DMD), exon skipping treatment to restore a wild-type phenotype or correct the frame shift of the mRNA transcript of the dystrophin (DMD) gene are mutation-specific. To explore the molecular characterization of DMD rearrangements and predict the reading frame, we simultaneously screened all 79 DMD gene exons of 45 unrelated male DMD patients using a multiplex ligation-dependent probe amplification (MLPA) assay for deletion/duplication patterns. Multiplex PCR was used to confirm single deletions detected by the MLPA. There was an obvious diagnostic delay, with an extremely statistically significant difference between the age at initial symptoms and the age of clinical evaluation of DMD cases (t value, 10.3; 95% confidence interval 5.95–8.80, P < 0.0001); the mean difference between the two groups was 7.4 years. Overall, we identified 147 intragenic rearrangements: 46.3% deletions and 53.7% duplications. Most of the deletions (92.5%) were between exons 44 and 56, with exon 50 being the most frequently involved (19.1%). Eight new rearrangements, including a mixed deletion/duplication and double duplications, were linked to seven cases with DMD. Of all the cases, 17.8% had duplications with no hot spots. In addition, confirmation of the reading frame hypothesis helped account for new DMD rearrangements in this study. We found that 81% of our Saudi patients would potentially benefit from exon skipping, of which 42.9% had a mutation amenable to skipping of exon 51. Our study could generate considerable data on mutational rearrangements that may promote future experimental therapies in Saudi Arabia.